YD Bio Limited Ordinary Shares
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.65 | $0 | -$298,190 |
| 2025 Q1 | -0.98 | $0 | -$490,410 |
| 2024 Q4 | 0.10 | $0 | -$365,650 |
| 2024 Q3 | 0.54 | $0 | -$21,570 |
| 2024 Q2 | 4.05 | $0 | -$592,520 |
| 2024 Q1 | -5.12 | $0 | -$629,740 |
| 2023 Q4 |
| 0.16 |
| $0 |
| -$688,420 |